YAP Inhibits Squamous Transdifferentiation of Lkb1-deficient Lung Adenocarcinoma Through ZEB2-dependent DNp63 Repression

Yijun Gao,Wenjing Zhang,Xiangkun Han,Fuming Li,Xujun Wang,Rui Wang,Zhaoyuan Fang,Xinyuan Tong,Shun Yao,Fei Li,Yan Feng,Yihua Sun,Yingyong Hou,Zhongzhou Yang,Kunliang Guan,Haiquan Chen,Lei Zhang,Hongbin Ji

DOI: https://doi.org/10.1038/ncomms5629

IF: 16.6

2014-01-01

Nature Communications

Abstract:Whether the Hippo pathway contributes to cell lineage transition under pathological conditions, especially tumorigenesis, remains largely unknown. Here we show that YAP, the major effector of the Hippo pathway, displays a distinct activation pattern in lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC); YAP is initially activated by LKB1 loss in lung ADC, which upregulates ZEB2 expression and represses DNp63 transcription in a default manner. During transdifferentiation, YAP is inactivated, which in turn relieves ZEB2-mediated default repression of DNp63 and triggers squamous differentiation reprogramming. Disruption of the YAP barrier for phenotypic transition significantly accelerates squamous transdifferentiation, whereas constitutive YAP activation conversely inhibits this transition. More importantly, ectopic DNp63 expression rescues the inhibitory effect of YAP on squamous transdifferentiation. These findings have established YAP as an essential barrier for lung cancer cell fate conversion and provided a mechanism for regulating cancer plasticity, which might hold important implication for YAP-targeted therapies. Lung adenocarcinomas can convert to squamous cell carcinomas, which is associated with cancer progression and therapy resistance. Here, Gao et al. identify YAP as an essential barrier for this phenotypic conversion through ZEB2-mediated DNP63 repression.